Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed
Mucosal-Associated Invariant T Cells in Multiple Sclerosis: The Jury is Still Out.
Potential role of immunoglobulin replacement therapy on MRI measures in multiple sclerosis: a systematic review.
[Foix-Chavany-Marie syndrome presenting as multiple sclerosis].
Clinical and Radiological Characterization of Progressive Multifocal Leukoencephalopathy in HIV-Infected Patients: A Retrospective Analysis and Review of the Literature.
Role of glial 14-3-3 gamma protein in autoimmune demyelination.
Suppression of Locomotor Activity in Female C57Bl/6J Mice Treated with Interleukin-1β: Investigating a Method for the Study of Fatigue in Laboratory Animals.
Improved Lesion Detection by Using Axial T2-Weighted MRI with Full Spinal Cord Coverage in Multiple Sclerosis.
Defective Autoimmune Regulator-Dependent Central Tolerance to Myelin Protein Zero Is Linked to Autoimmune Peripheral Neuropathy.
What are exosomes and how can they be used in multiple sclerosis therapy?
Composite end points to assess delay of disability progression by MS treatments.
Changes of statistical structural fluctuations unveils an early compacted degraded stage of PNS myelin.
[Immunotherapies for multiple sclerosis : Review and update.]
Epigenetic mechanisms in neurological and neurodegenerative diseases.
Catatonia and klüver-bucy syndrome in a patient with acute disseminated encephalomyelitis.
Translating Neurogenomics into New Medicines.
miFRame: analysis and visualization of miRNA sequencing data in neurological disorders.
Peculiar Cytological Cerebrospinal Fluid Pattern in a Case of Encephalomyelitis During Anti-Tumor Necrosis Factor-α Therapy.
The killer immunoglobulin-like receptor KIR3DL1 in combination with HLA-Bw4 is protective against multiple sclerosis in African Americans.
The role of dopamine in modulation of Th-17 immune response in multiple sclerosis.
Development of a Short Version of MSQOL-54 Using Factor Analysis and Item Response Theory.
Low quality of life and psychological wellbeing contrast with moderate perceived burden in carers of people with severe multiple sclerosis.
Hunting for autoantibodies in multiple sclerosis.
Outcomes after Microvascular Decompression for Patients with Trigeminal Neuralgia and Suspected Multiple Sclerosis.
Tumefactive multiple sclerosis and fingolimod: Immunotherapies and unintended consequences.
Comparison of serum levels of copper and zinc among multiple sclerosis patients and control group.
Pages
« first
‹ previous
…
611
612
613
614
615
616
617
618
619
…
next ›
last »